Medtronic Touts 3-year EverFlex Stent Data
Friday, April 3, 2015
Source: Mass Device
Medtronic (NYSE:MDT) is touting solid 3-year results for the EverFlex self-expanding peripheral stent system it picked up when it paid $50 billion for Covidien in January.
The global medical device giant said 3-year results from the Durability II study of Everflex showed the single-stent treatment had sustained effect in addressing long, complex lesions in the superficial femoral and popliteal arteries and keeping them unobstructed.